Literature DB >> 12161492

Anticoagulant prophylaxis markedly reduces thromboembolic complications in Cushing's syndrome.

Marco Boscaro1, Nicoletta Sonino, Alessandro Scarda, Luisa Barzon, Francesco Fallo, Maria T Sartori, Giovanni M Patrassi, Antonio Girolami.   

Abstract

A hypercoagulable state and an increased incidence of thromboembolic complications are reported in Cushing's syndrome. The hypercoagulable state is related to an increase in plasma clotting factors, especially Factor VIII and von Willebrand factor complex, and to an impairment of fibrinolytic capacity. Retrospective analysis of postoperative thromboembolic events in a large group of patients with Cushing's syndrome, including 75 patients (group 1) evaluated in the period from 1972-1981 not receiving anticoagulants, and 232 patients (group 2), evaluated in the period from 1982-2000. Patients of group 1 underwent routine hemostatic function, i.e. prothrombin time and activated partial thromboplastine time. Patients of group 2 underwent a thorough investigation as to hemostatic parameters and received prophylactic treatment with heparin and/or warfarin. Patients with Cushing's syndrome showed various abnormalities of hemostatic parameters. A significant correlation between activated partial thromboplastine time and urinary free cortisol was observed. During follow-up, 15 patients (20%; mean follow-up, 9.4 +/- 6.4 yr) of group 1 and 14 (6.0%; mean follow-up, 6.6 +/- 4.2 yr) of group 2 showed thromboembolic complications. Of these patients, eight of group 1 and one of group 2 died. Survival analysis demonstrated a significantly higher morbidity and mortality due to thromboembolic events in group 1, not receiving anticoagulant prevention, than in group 2, treated with anticoagulants in the perioperative period until cure of the disease and normalization of clotting parameters. Cushing's syndrome is associated with a hypercoagulable state. An adequate anticoagulant prophylaxis can reverse this prothrombotic state and avoid postoperative thromboembolic events.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12161492     DOI: 10.1210/jcem.87.8.8703

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  43 in total

Review 1.  5th International ACC Symposium: Old Syndromes with New Biomarkers and New Therapies with Old Medications.

Authors:  Sarika N Rao; Mouhammed Amir Habra
Journal:  Horm Cancer       Date:  2015-12-10       Impact factor: 3.869

2.  Elevated plasma von Willebrand factor levels in patients with active ulcerative colitis reflect endothelial perturbation due to systemic inflammation.

Authors:  Petros Zezos; Georgia Papaioannou; Nikolaos Nikolaidis; Themistoclis Vasiliadis; Olga Giouleme; Nikolaos Evgenidis
Journal:  World J Gastroenterol       Date:  2005-12-28       Impact factor: 5.742

3.  Extensive and largely reversible ischemic cerebral infarctions in a prepubertal child with hypertension and Cushing disease.

Authors:  Jil Huong Nguyen; Maya B Lodish; Nicholas J Patronas; Figen Ugrasbul; Margaret F Keil; Mary D Roberts; Jadranka Popovic; Constantine A Stratakis
Journal:  J Clin Endocrinol Metab       Date:  2009-01       Impact factor: 5.958

Review 4.  Cardiovascular risk in Cushing's syndrome.

Authors:  Giorgio Arnaldi; Tatiana Mancini; Barbara Polenta; Marco Boscaro
Journal:  Pituitary       Date:  2004       Impact factor: 4.107

5.  Lateral retroperitoneoscopic adrenalectomy: advantages and drawbacks.

Authors:  Konstantin Grozdev; Nabil Khayat; Svetlana Shumarova; Gergana Ivanova; Kostadin Angelov; Georgi Todorov
Journal:  Updates Surg       Date:  2020-03-11

Review 6.  The Treatment of Cushing's Disease.

Authors:  Rosario Pivonello; Monica De Leo; Alessia Cozzolino; Annamaria Colao
Journal:  Endocr Rev       Date:  2015-06-11       Impact factor: 19.871

7.  Coagulation Profile Dynamics in Pediatric Patients with Cushing Syndrome: A Prospective, Observational Comparative Study.

Authors:  Leah Birdwell; Maya Lodish; Amit Tirosh; Prashant Chittiboina; Meg Keil; Charlampos Lyssikatos; Elena Belyavskaya; Richard A Feelders; Constantine A Stratakis
Journal:  J Pediatr       Date:  2016-08-02       Impact factor: 4.406

Review 8.  Cushing's disease.

Authors:  Martina De Martin; Francesca Pecori Giraldi; Francesco Cavagnini
Journal:  Pituitary       Date:  2006       Impact factor: 4.107

9.  Biochemical markers for cardiovascular risk following treatment in endogenous Cushing's syndrome.

Authors:  C Kristo; T Ueland; K Godang; P Aukrust; J Bollerslev
Journal:  J Endocrinol Invest       Date:  2008-05       Impact factor: 4.256

10.  Hypercoagulability in patients with Cushing disease detected by thrombin generation assay is associated with increased levels of neutrophil extracellular trap-related factors.

Authors:  Armando Tripodi; Concetta T Ammollo; Fabrizio Semeraro; Mario Colucci; Elena Malchiodi; Elisa Verrua; Emanuele Ferrante; Giorgio Arnaldi; Laura Trementino; Lidia Padovan; Veena Chantarangkul; Flora Peyvandi; Giovanna Mantovani
Journal:  Endocrine       Date:  2016-07-22       Impact factor: 3.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.